PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2007 | 54 |
| 2008 | 73 |
| 2009 | 63 |
| 2010 | 55 |
| 2011 | 65 |
| 2012 | 84 |
| 2013 | 112 |
| 2014 | 187 |
| 2015 | 149 |
| 2016 | 96 |
| 2017 | 136 |
| 2018 | 158 |
| 2019 | 195 |
| 2020 | 253 |
| 2021 | 254 |
| 2022 | 184 |
| 2023 | 199 |
| 2024 | 224 |
| 2025 | 216 |
| 2026 | 157 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Mol Oncol"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
Optimization of seminal extracellular vesicle isolation protocols for cancer biomarker analysis using proteomic profiling.
- Telumyan E, Martín-Gracia B, Bassols-Citores E, Sagini K, Andersen MK, Nyman TA, Tessem MB, Rye MB, Llorente A.
- Mol Oncol. 2026 Oct 22:10.1002/1878-0261.70345. doi: 10.1002/1878-0261.70345. Online ahead of print.
- PMCID: PMC13688550
Telumyan E, et al.Mol Oncol. 2026.PMCID: PMC13688550 -
Attitudes of cancer patients toward ctDNA-based liquid biopsy for follow-up.
- Chhajlani S, Mariën L, De Weerdt C, Wouters S, Teuwen LA, Prenen H, Janssens K, Vandamme T.
- Mol Oncol. 2026 Oct 21:10.1002/1878-0261.70352. doi: 10.1002/1878-0261.70352. Online ahead of print.
- PMCID: PMC13685910
Chhajlani S, et al.Mol Oncol. 2026.PMCID: PMC13685910 -
A role for eIF5A in translational control of stress-inducible proteins in multiple myeloma cell lines.
- Both D, Derks IAM, Vanleyssem R, Leclercq M, El Hachem N, Close P, Eldering E, Haselager MV.
- Mol Oncol. 2026 Oct 21:10.1002/1878-0261.70328. doi: 10.1002/1878-0261.70328. Online ahead of print.
- PMCID: PMC13685402
Both D, et al.Mol Oncol. 2026.PMCID: PMC13685402 -
USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival.
- Almuhanna HNB, Hay J, Moles MW, Clarke L, Cassels J, Sefcick A, McCaig AM, Jørgensen HG, Michie AM.
- Mol Oncol. 2026 Oct 21:10.1002/1878-0261.70350. doi: 10.1002/1878-0261.70350. Online ahead of print.
- PMCID: PMC13685403
Almuhanna HNB, et al.Mol Oncol. 2026.PMCID: PMC13685403 -
Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers.
- David M, Karaulic A, Bennetot A, Fournier C, Odet Q, Gouraud A, Bourget I, Gaggioli C, Giuliano S, Luciano F, Léger O, Sellam Z, Pagès G.
- Mol Oncol. 2026 Oct 20:10.1002/1878-0261.70343. doi: 10.1002/1878-0261.70343. Online ahead of print.
- PMCID: PMC13682602
David M, et al.Mol Oncol. 2026.PMCID: PMC13682602 -
RETRACTION: Recombinant Nanobody Against Muc1 Tandem Repeats Inhibits Growth, Invasion, Metastasis, and Vascularization of Spontaneous Mouse Mammary Tumors.
- [No authors listed]
- Mol Oncol. 2026 Oct 20:10.1002/1878-0261.70348. doi: 10.1002/1878-0261.70348. Online ahead of print.
- PMCID: PMC13682140
-
- Retracts: Mol Oncol. 2022 Jan;16(2):485-507. doi: 10.1002/1878-0261.13123. PubMed Abstract
[No authors listed]Mol Oncol. 2026.PMCID: PMC13682140Retraction notice. -
Tumour-proximal deep serum proteomics identifies biomarkers associated with ovarian cancer.
- Lau D, Pincher D, Young C, Chappell N, Lokman NA, Mittal P, Donnellan L, Oehler MK, Brooks DA, Hoffmann P.
- Mol Oncol. 2026 Oct 17:10.1002/1878-0261.70351. doi: 10.1002/1878-0261.70351. Online ahead of print.
- PMCID: PMC13675746
Lau D, et al.Mol Oncol. 2026.PMCID: PMC13675746 -
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy.
- Serra-Mir G, Haro-Martínez E, Blasco-Benito S, Cannatà C, Palomeque JÁ, López-Plana A, Sanz-Flores M, Sabartés M, Fornaguera C, Celià-Terrassa T.
- Mol Oncol. 2026 Oct 15:10.1002/1878-0261.70344. doi: 10.1002/1878-0261.70344. Online ahead of print.
- PMCID: PMC13670883
Serra-Mir G, et al.Mol Oncol. 2026.PMCID: PMC13670883 -
Spatial heterogeneity of hotspot mutations and clonal relatedness in ovarian endometrioid carcinoma.
- Ashihara T, Murakami K, Takamatsu S, Kanto A, Mori S, Otani T, Sakai K, Kotani Y, Nishio K, Abiko K, Matsumura N.
- Mol Oncol. 2026 Oct 8:10.1002/1878-0261.70347. doi: 10.1002/1878-0261.70347. Online ahead of print.
- PMCID: PMC13648112
Ashihara T, et al.Mol Oncol. 2026.PMCID: PMC13648112 -
Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer.
- Chambuso RS, Ul Islam MS, Xicola RM, Ramesar R, Llor X, Steele S.
- Mol Oncol. 2026 Oct 7:10.1002/1878-0261.70338. doi: 10.1002/1878-0261.70338. Online ahead of print.
- PMCID: PMC13643886
Chambuso RS, et al.Mol Oncol. 2026.PMCID: PMC13643886